» Articles » PMID: 35541710

Retracted Article: Ligustrazine Attenuates Renal Damage by Inhibiting Endoplasmic Reticulum Stress in Diabetic Nephropathy by Inactivating MAPK Pathways

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 May 11
PMID 35541710
Authors
Affiliations
Soon will be listed here.
Abstract

: Diabetic nephropathy (DN) is a major cause of chronic kidney disease around the world. Endoplasmic reticulum (ER) stress plays an important role in DN progression. Ligustrazine (Lig) is derived from the Chinese herb and is reported to exert anti-oxidant, anti-inflammation and anti-fibrosis effects. The aim of our study was to investigate the influence of Lig on the treatment of DN. : Streptozotocin (STZ) was used to induce diabetes in Sprague-Dawley (SD) rats. Then, STZ-induced rats were treated with different concentrations of Lig (50 or 150 mg kg day) for 8 weeks of treatment. Urinary albumin concentrations, blood urea nitrogen (BUN), serum creatinine (Scr) and creatinine clearance (Ccr) were determined. The levels of proinflammatory cytokines (IL-8, IL-6, IL-1β and TNF-α) were estimated by ELISA. TUNEL assay was used for apoptosis index measurement. Western blot was used for the detection of GRP78, CHOP, p-eIF2α, eIF2α, p-p38, p-38, p-ERK1/2 and ERK1/2. : Lig treatment significantly reduced urinary albumin excretion, BUN and Scr and increased Ccr in STZ-induced rats. Lig also suppressed the levels of IL-8, IL-6, IL-1β and TNF-α and inhibited apoptosis dose-dependently. In addition, Lig inhibited GRP78 and CHOP expression and prevented the phosphorylation of eIF2α, p-38 and ERK1/2. : Our study indicated that Lig attenuated renal damage by inhibiting ER stress in DN by inactivating MAPK pathways.

Citing Articles

Nephroprotective effects of Aralia taibaiensis in a high-fat diet-streptozotocin rat model of diabetic nephropathy.

Cui J, Wang M, Liu M, Jia N, Zhao M, Weng Y Heliyon. 2024; 10(11):e31775.

PMID: 38947426 PMC: 11214440. DOI: 10.1016/j.heliyon.2024.e31775.


BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways.

Khamis T, Abdelkhalek A, Abdellatif H, Dwidar N, Said A, Ahmed R Front Pharmacol. 2023; 14:1265230.

PMID: 38044936 PMC: 10690373. DOI: 10.3389/fphar.2023.1265230.


Retraction: Resveratrol attenuates inflammation and reduces matrix-metalloprotease expression by inducing autophagy suppressing the Wnt/β-catenin signaling pathway in IL-1β-induced osteoarthritis chondrocytes.

Fisher L RSC Adv. 2022; 11(7):4209.

PMID: 35747362 PMC: 9133985. DOI: 10.1039/d1ra90015c.


Retraction: Vitexin mitigates myocardial ischemia reperfusion-induced damage by inhibiting excessive autophagy to suppress apoptosis the PI3K/Akt/mTOR signaling cascade.

Fisher L RSC Adv. 2022; 11(8):4440.

PMID: 35426991 PMC: 8694545. DOI: 10.1039/d1ra90024b.


Retraction: Salvianolic acid B inhibits inflammatory response and cell apoptosis the PI3K/Akt signaling pathway in IL-1β-induced osteoarthritis chondrocytes.

Fisher L RSC Adv. 2022; 11(8):4441.

PMID: 35426988 PMC: 8694433. DOI: 10.1039/d1ra90026a.


References
1.
Wang G, Lu X, Li W, Zhao X, Zhang C . Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2011; 2011:323171. PMC: 3092543. DOI: 10.1155/2011/323171. View

2.
Lindenmeyer M, Rastaldi M, Ikehata M, Neusser M, Kretzler M, Cohen C . Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol. 2008; 19(11):2225-36. PMC: 2573014. DOI: 10.1681/ASN.2007121313. View

3.
McAlpine C, Werstuck G . The development and progression of atherosclerosis: evidence supporting a role for endoplasmic reticulum (ER) stress signaling. Cardiovasc Hematol Disord Drug Targets. 2013; 13(2):158-64. DOI: 10.2174/1871529x11313020009. View

4.
Fan Y, Xiao W, Li Z, Li X, Chuang P, Jim B . RTN1 mediates progression of kidney disease by inducing ER stress. Nat Commun. 2015; 6:7841. PMC: 4532799. DOI: 10.1038/ncomms8841. View

5.
Nelson R, Tuttle K . Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. Am J Kidney Dis. 2009; 55(3):426-30. PMC: 3480512. DOI: 10.1053/j.ajkd.2009.10.001. View